Revisions to Brazil's drug price framework are coming - what's included and what's missing? Our analysts provide th… https://t.co/8s17gnKCXf
Who we are
An independent and holistic view of global healthcare and pharmaceutical markets
We offer comprehensive and independent coverage of pricing and reimbursement developments, processes and market trends alongside award-winning economic data and analysis, enabling our customers to optimize market access and revenue.
With unique data, analytics and tools produced by our team of experts, we help you monitor and quantify the global impact of the competitive pricing and reimbursement environment, market access and tendering strategies, disease trends and therapeutic breakthroughs, evolving healthcare budget and expenditures, healthcare workforce needs and much more.
Contact UsView global sales phone numbers
Life Sciences Products & Solutions
Pharmaceutical Pricing & Market Access Strategy
Engineering Intelligence for Medical Devices
Not sure what product you need?
A trained health economist, he brings more than 20 years of experience conducting research and policy analysis in the areas of health economics and outcomes, health workforce, health care delivery and disease cost and prevention. His work applies economic theory, statistical and econometric analysis, cost/benefit analysis, program evaluation, and computer modeling skills. Much of his work uses microsimulation modeling to address complex forecasting and policy issues. Applied research conducted by Mr. Dall supports strategic planning and advocacy work for governments, associations, life sciences companies, payers, provider networks, and non-profit organizations. He has published widely in peer-reviewed journals. Mr. Dall earned his Master of Science in Labor Economics at the University of Wisconsin-Madison, US, and his Bachelor of Science in Economics from Utah State University, Logan, Utah, US.
Blogs & AnalysisView All
Brazil finally edges towards first drug pricing reform after two years – is it a missed opportunity?
Variations on an IRP theme: How payers are repurposing pricing policies for new categories of medicines
Pharmaceutical and healthcare sectors jointly top global PMI ranking for first time
Hire industry-leading consultants by the hour. Get the objective, authoritative analysis you need without delays.